In The News

Biokin Pharmaceutical Launches Shanghai Initial Public Offering

Chengdu, China Jan, 2023

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

Redmond, Washington May 13rd, 2022

SystImmune Inc Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

Redmond, Washington February 7th, 2022

Systimmune Inc. Announces SI-F019 As a Blocker of Viral Entry against SARSCoV-2 with Reduced Inflammatory Risk

Redmond, Washington March, 2020

High Throughput Application of High Resolution LC-MS for Upstream and Downstream Biotherapeutics Process Development

Pleasanton, California August, 2018

ACS National Meeting 2018 - Rapid aggregate reduction of bi-specific antibody model by filtration

New Orleans, Louisiana March, 2018